Related Experiment Video
Updated: Aug 31, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY
E Leistad1, G Aksnes, E Verburg
1Institute for Experimental Medical Research, University of Oslo, Ullevål Hospital, Norway. elizabeth.leistad@ioks.uio.no
Insights
Calcium channel blocker verapamil reduced atrial contractile dysfunction after atrial fibrillation, suggesting calcium influx contributes to this condition. The calcium agonist BAY K8644 worsened dysfunction.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Atrial contractility is reduced after atrial fibrillation cessation.
- The mechanism of this post-fibrillation atrial dysfunction is unknown.
- Intracellular calcium overload from rapid depolarization is a hypothesized cause.
Purpose of the Study:
- To investigate the role of transsarcolemmal calcium influx in post-fibrillation atrial dysfunction.
- To examine the effects of calcium channel blockers and agonists on this dysfunction.
- To determine if atrial ischemia contributes to the observed dysfunction.
Main Methods:
- Open-chest pigs with induced atrial fibrillation were studied.
- Atrial contractility was measured by left atrial diameter shortening.
- Verapamil (calcium antagonist) or BAY K8644 (calcium agonist) was administered before the second fibrillation period.
Main Results:
- Verapamil reduced the degree and duration of post-fibrillation atrial contractile dysfunction.
- BAY K8644 increased post-fibrillation atrial contractile dysfunction.
- Atrial tissue levels of creatine phosphate decreased slightly; ATP and lactate remained unchanged, indicating no significant ischemia.
Conclusions:
- Transsarcolemmal calcium influx contributes to atrial contractile dysfunction following atrial fibrillation.
- Calcium channel antagonism (verapamil) ameliorates this dysfunction.
- Calcium channel agonism (BAY K8644) exacerbates post-fibrillation atrial contractile dysfunction.
Background:
Reduced atrial contractility occurs after cessation of atrial fibrillation. Its mechanism is unknown, and no pharmacological treatment exists. It has been hypothesized that this atrial contractile dysfunction results from intracellular calcium overload due to rapid depolarizations during fibrillation. Accordingly, we examined the effects of drugs that reduce or increase transsarcolemmal calcium influx on postfibrillation atrial dysfunction. Furthermore, we examined whether the dysfunction could be attributed to atrial ischemia.
Methods And Results:
Atrial contractility after atrial fibrillation was examined in open-chest pigs paced with a constant ventricular rate after complete AV block. Atrial contractility was computed as systolic shortening of left atrial diameter divided by atrial preload. Three groups of six pigs each were subjected to two 5-minute periods of atrial fibrillation separated by 1 hour of AV pacing. Verapamil or the calcium channel agonist BAY K8644 was administered intravenously before the second fibrillation period. The degree and duration of postfibrillation atrial contractile dysfunction were reduced with verapamil but increased with BAY K8644. In a control group, parallel changes occurred after the first and second fibrillation periods. Atrial tissue content of creatine phosphate declined slightly during fibrillation, whereas the tissue content of ATP and lactate remained unchanged.
Conclusions:
Atrial contractile dysfunction after short-term atrial fibrillation is reduced by the calcium antagonist verapamil, which suggests that transsarcolemmal calcium influx contributed to this dysfunction. The calcium agonist BAY K8644 increased postfibrillation atrial contractile dysfunction. Atrial ischemia was not observed during fibrillation.
More Related Videos
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

